Summit Therapeutics (SMMT)
Summit Therapeutics on one page: short interest, daily short volume, fails to deliver, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
41.2M
Short interest
settlement 2026-09-30
4.8
Days to cover
-1.7 days vs prior
64.9%
Short share of volume
2026-10-09
2,062
Fails to deliver
settlement 2026-09-14
Mon 19 Oct
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-10-09.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 30 September 2026, short interest in SMMT is 41,155,196 shares, down 175,156 shares over the last month. Over the last 48 readings it ranged from 15,446,534 shares (15 October 2024) to 41,330,352 shares (31 August 2026). The latest reading sits at the top of that range. At the reported average volume of 8.5M shares a day that is 4.8 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/smmt" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-09-30 | 41,155,196 | +0.2% | 8,495,750 | 4.84 |
| 2026-09-15 | 41,081,179 | -0.6% | 6,260,891 | 6.56 |
| 2026-08-31 | 41,330,352 | +10.4% | 6,240,461 | 6.62 |
| 2026-08-14 | 37,432,330 | +3.3% | 4,308,749 | 8.69 |
| 2026-07-31 | 36,245,370 | -2.9% | 4,091,058 | 8.86 |
| 2026-07-15 | 37,327,940 | -6.3% | 3,386,533 | 11.02 |
| 2026-06-30 | 39,855,640 | +8.3% | 5,958,124 | 6.69 |
| 2026-06-15 | 36,811,691 | +1.9% | 8,254,320 | 4.46 |
| 2026-05-29 | 36,126,988 | +21.2% | 4,410,564 | 8.19 |
| 2026-05-15 | 29,818,472 | +2.1% | 4,731,678 | 6.30 |
| 2026-04-30 | 29,194,577 | -15.4% | 5,240,834 | 5.57 |
| 2026-04-15 | 34,504,458 | -0.2% | 2,298,337 | 15.01 |
| 2026-03-31 | 34,558,050 | -4.3% | 2,798,782 | 12.35 |
| 2026-03-13 | 36,116,187 | +4.2% | 2,265,734 | 15.94 |
| 2026-02-27 | 34,669,041 | -8.4% | 1,712,273 | 20.25 |
| 2026-02-13 | 37,869,822 | +2.5% | 2,715,151 | 13.95 |
| 2026-01-30 | 36,964,760 | -0.6% | 3,038,813 | 12.16 |
| 2026-01-15 | 37,198,664 | +0.5% | 3,297,916 | 11.28 |
| 2025-12-31 | 37,009,569 | +3.5% | 1,989,245 | 18.60 |
| 2025-12-15 | 35,753,740 | +10.5% | 2,689,226 | 13.30 |
| 2025-11-28 | 32,347,593 | +3.6% | 2,304,436 | 14.04 |
| 2025-11-14 | 31,236,590 | -3.7% | 2,501,115 | 12.49 |
| 2025-10-31 | 32,436,319 | +0.5% | 4,127,767 | 7.86 |
| 2025-10-15 | 32,272,331 | -10.2% | 2,797,355 | 11.54 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 9 October 2026, the short share of SMMT volume is 64.9%, up 15.6 points over the last five sessions. Over the last 30 readings it ranged from 47.2% (4 September 2026) to 73.3% (17 September 2026). The latest reading is 7.7 points above the 30-session average of 57.1%, on 2.5M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-10-09 | 1.6M | 2.5M | 64.9% | 0 |
| 2026-10-08 | 1.5M | 2.7M | 55.9% | 2,504 |
| 2026-10-07 | 2.3M | 4.0M | 57.9% | 2,590 |
| 2026-10-06 | 1.2M | 2.4M | 48.9% | 20,960 |
| 2026-10-05 | 1.1M | 2.1M | 54.2% | 1,026 |
| 2026-10-02 | 989K | 2.0M | 49.3% | 2,163 |
| 2026-10-01 | 1.6M | 2.9M | 53.6% | 11,883 |
| 2026-09-30 | 2.9M | 5.7M | 50.5% | 19,426 |
| 2026-09-29 | 8.0M | 12.1M | 65.6% | 36,637 |
| 2026-09-28 | 872K | 1.5M | 59.0% | 3,100 |
| 2026-09-25 | 797K | 1.5M | 53.0% | 351 |
| 2026-09-24 | 1.3M | 2.1M | 60.7% | 1,653 |
| 2026-09-23 | 862K | 1.5M | 56.9% | 5,193 |
| 2026-09-22 | 1.1M | 1.7M | 67.6% | 0 |
| 2026-09-21 | 1.4M | 2.5M | 57.4% | 1,500 |
| 2026-09-18 | 810K | 1.2M | 68.1% | 16 |
| 2026-09-17 | 1.9M | 2.6M | 73.3% | 2,081 |
| 2026-09-16 | 1.2M | 2.1M | 56.8% | 0 |
| 2026-09-15 | 1.6M | 2.7M | 60.3% | 34 |
| 2026-09-14 | 2.2M | 3.6M | 60.6% | 14,657 |
| 2026-09-11 | 1.2M | 2.0M | 58.9% | 3,645 |
| 2026-09-10 | 1.1M | 1.9M | 57.9% | 5,152 |
| 2026-09-09 | 1.3M | 1.9M | 65.8% | 6,594 |
| 2026-09-08 | 1.4M | 2.6M | 56.1% | 9,129 |
| 2026-09-04 | 1.2M | 2.5M | 47.2% | 9,312 |
| 2026-09-03 | 3.0M | 6.2M | 48.9% | 31,457 |
| 2026-09-02 | 525K | 1.0M | 50.3% | 15,700 |
| 2026-09-01 | 787K | 1.6M | 48.2% | 5,300 |
| 2026-08-31 | 605K | 1.1M | 57.6% | 0 |
| 2026-08-28 | 662K | 1.4M | 48.0% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 September 2026, the fails-to-deliver balance in SMMT is 2,062 shares, down 338,948 shares over the last settlement date. Over the last 30 readings it ranged from 10 shares (23 July 2026) to 564,332 shares (11 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-14 | 2,062 | $17.55 | $36K |
| 2026-09-09 | 341,010 | $17.28 | $5.9M |
| 2026-09-08 | 29,684 | $17.61 | $523K |
| 2026-09-04 | 66,143 | $17.13 | $1.1M |
| 2026-09-03 | 140,668 | $14.60 | $2.1M |
| 2026-08-26 | 4,447 | $13.36 | $59K |
| 2026-08-25 | 28,983 | $12.73 | $369K |
| 2026-08-10 | 86,636 | $13.96 | $1.2M |
| 2026-08-04 | 5,120 | $13.05 | $67K |
| 2026-07-24 | 54 | $14.98 | $809 |
| 2026-07-23 | 10 | $14.74 | $147 |
| 2026-07-21 | 1,074 | $13.50 | $14K |
| 2026-07-17 | 1,087 | $13.76 | $15K |
| 2026-07-06 | 8,095 | $15.42 | $125K |
| 2026-07-01 | 1,060 | $14.57 | $15K |
| 2026-06-30 | 24,039 | $14.32 | $344K |
| 2026-06-26 | 7,031 | $14.18 | $100K |
| 2026-06-23 | 183,560 | $14.28 | $2.6M |
| 2026-06-22 | 183,560 | $13.75 | $2.5M |
| 2026-06-18 | 24,473 | $14.07 | $344K |
| 2026-06-17 | 80,037 | $13.88 | $1.1M |
| 2026-06-16 | 30 | $14.13 | $424 |
| 2026-06-15 | 35,684 | $14.01 | $500K |
| 2026-06-11 | 564,332 | $13.05 | $7.4M |
| 2026-06-10 | 954 | $14.29 | $14K |
| 2026-06-09 | 42,023 | $14.11 | $593K |
| 2026-06-08 | 41,666 | $14.77 | $615K |
| 2026-06-04 | 1,253 | $15.07 | $19K |
| 2026-06-03 | 507 | $14.86 | $8K |
| 2026-06-02 | 17,315 | $15.71 | $272K |
Insider trades
SEC Form 4, newest first, 50 of 70 shown. JSONNo open-market insider trades were reported for SMMT in the last 90 days. The most recent filings are listed below. Latest filing: DUGGAN ROBERT W (Co-Chief Executive Officer) on 2026-06-12.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-12 | DUGGAN ROBERT W | Co-Chief Executive Officer | Buy | 3.8M | $13.12 | $50.0M | 573.9M |
| 2026-06-12 | Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 3.8M | $13.12 | $50.0M | 573.9M |
| 2026-06-04 | Soni Manmeet Singh | COO and CFO | Buy | 25K | $14.43 | $361K | 3.1M |
| 2026-06-04 | Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 100K | $14.60 | $1.5M | 25.8M |
| 2026-06-04 | Soni Manmeet Singh | COO and CFO | Buy | 25K | $14.46 | $362K | 3.1M |
| 2026-06-04 | DUGGAN ROBERT W | Co-Chief Executive Officer | Buy | 100K | $14.60 | $1.5M | 25.8M |
| 2025-10-21 | Xia Yu | Director | Buy | 534K | $18.74 | $10.0M | 32.1M |
| 2025-10-21 | Zanganeh Mahkam | Co-Chief Executive Officer | Grant | 14.0M | $18.74 | $262.0M | 570.1M |
| 2025-10-21 | Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 27K | $18.74 | $500K | 77K |
| 2025-10-21 | Zanganeh Mahkam | Co-Chief Executive Officer | Grant | 267K | $18.74 | $5.0M | 25.7M |
| 2025-10-21 | Soni Manmeet Singh | COO and CFO | Grant | 53K | $18.74 | $1000K | 3.1M |
| 2025-10-21 | DUGGAN ROBERT W | Co-Chief Executive Officer | Buy | 27K | $18.74 | $500K | 77K |
| 2025-10-21 | DUGGAN ROBERT W | Co-Chief Executive Officer | Grant | 267K | $18.74 | $5.0M | 25.7M |
| 2025-10-21 | DUGGAN ROBERT W | Co-Chief Executive Officer | Grant | 14.0M | $18.74 | $262.0M | 570.1M |
| 2025-10-21 | Anand Bhaskar | Chief Accounting Officer | Grant | 27K | $18.74 | $500K | 160K |
| 2025-09-11 | Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 5K | $18.07 | $90K | 556.1M |
| 2025-09-11 | DUGGAN ROBERT W | Co-Chief Executive Officer | Buy | 5K | $18.07 | $90K | 556.1M |
| 2025-09-10 | Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 333K | $17.68 | $5.9M | 556.1M |
| 2025-09-10 | DUGGAN ROBERT W | Co-Chief Executive Officer | Buy | 333K | $17.68 | $5.9M | 556.1M |
| 2025-05-30 | DUGGAN ROBERT W | Co-Chief Executive Officer | Option exercise | 75K | $2.64 | $197K | 555.8M |
| 2025-05-30 | Zanganeh Mahkam | Co-Chief Executive Officer | Option exercise | 75K | $2.64 | $197K | 555.8M |
| 2025-04-08 | DUGGAN ROBERT W | Co-Chief Executive Officer | X | 4.0M | $1.58 | $6.3M | 555.7M |
| 2025-04-08 | Zanganeh Mahkam | Co-Chief Executive Officer | X | 4.0M | $1.58 | $6.3M | 555.7M |
| 2024-10-03 | Zanganeh Mahkam | Co-Chief Executive Officer | X | 316K | $1.58 | $499K | 10.2M |
| 2024-09-11 | Anand Bhaskar | Chief Accounting Officer | Grant | 22K | $22.70 | $500K | 131K |
| 2024-09-11 | Soni Manmeet Singh | COO and CFO | Grant | 44K | $22.70 | $1000K | 3.0M |
| 2024-09-11 | Huber Jeff | Director | Grant | 44K | $22.70 | $1000K | 44K |
| 2024-09-11 | DUGGAN ROBERT W | Co-Chief Executive Officer | Grant | 3.3M | $22.70 | $75.5M | 551.7M |
| 2024-09-11 | Zanganeh Mahkam | Co-Chief Executive Officer | Grant | 44K | $22.70 | $1000K | 25.0M |
| 2024-03-27 | Zanganeh Mahkam | Chief Executive Officer | Buy | 26K | $3.72 | $97K | 521K |
| 2024-03-27 | Zanganeh Mahkam | Chief Executive Officer | Buy | 34K | $3.72 | $128K | 24.9M |
| 2024-03-27 | Zanganeh Mahkam | Chief Executive Officer | Buy | 20K | $3.71 | $74K | 50K |
| 2024-03-26 | Dhingra Ankur | Chief Financial Officer | Buy | 100K | $3.75 | $375K | 355K |
| 2024-03-26 | Zanganeh Mahkam | Chief Executive Officer | Buy | 30K | $3.75 | $113K | 30K |
| 2023-12-13 | Dhingra Ankur | Chief Financial Officer | Buy | 20K | $2.17 | $43K | 255K |
| 2023-12-13 | Dhingra Ankur | Chief Financial Officer | Buy | 700 | $2.15 | $2K | 235K |
| 2023-12-12 | Zanganeh Mahkam | Chief Executive Officer | Buy | 5K | $2.07 | $10K | 495K |
| 2023-12-11 | Zanganeh Mahkam | Chief Executive Officer | X | 490K | $1.44 | $705K | 490K |
| 2023-12-11 | Zanganeh Mahkam | Chief Executive Officer | X | 316K | $1.58 | $499K | 24.9M |
| 2023-10-13 | Soni Manmeet Singh | Chief Operating Officer | Buy | 3.0M | $1.68 | $5.0M | 3.0M |
| 2023-03-08 | Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 805K | $1.05 | $845K | 1.2M |
| 2023-03-08 | Zanganeh Mahkam | Co-Chief Executive Officer | Buy | 16.0M | $1.05 | $16.8M | 23.4M |
| 2023-03-08 | Zanganeh Mahkam | Co-CEO & President | Buy | 6.7M | $1.05 | $7.1M | 9.9M |
| 2023-03-08 | Zanganeh Mahkam | Co-CEO & President | Buy | 16.8M | $1.05 | $17.6M | 24.6M |
| 2023-03-07 | Dhingra Ankur | Chief Financial Officer | Buy | 196K | $1.05 | $206K | 235K |
| 2023-03-06 | DUGGAN ROBERT W | Chief Executive Officer | Buy | 376.5M | $1.05 | $395.3M | 552.4M |
| 2022-12-06 | DUGGAN ROBERT W | Chief Executive Officer | J | 9.3M | price not stated in the filing | not stated | 171.9M |
| 2022-12-06 | Zanganeh Mahkam | Co-CEO & President | J | 374K | price not stated in the filing | not stated | 10.9M |
| 2022-08-16 | Dhingra Ankur | Chief Financial Officer | Buy | 13K | $0.97 | $13K | 40K |
| 2022-08-16 | Dhingra Ankur | Chief Financial Officer | Buy | 12K | $0.97 | $11K | 38K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
13F holders
Tracked managers holding SMMT at their latest 13F. JSON6 of the 30 tracked managers held SMMT at their latest 13F, $149.4M in total at quarter-end prices. Point72 Asset Management is the largest at $53.9M (0.1% of its portfolio) as of 2026-06-30. Over the prior quarter 4 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Point72 Asset Management | 2026-06-30 | 3.7M | $53.9M | 0.06% | +2.9M |
| Millennium Management | 2026-06-30 | 2.3M | $34.2M | 0.01% | +2.2M |
| Citadel Advisors | 2026-06-30 | 1.7M | $25.1M | 0.00% | +1.3M |
| D. E. Shaw & Co. | 2026-06-30 | 1.2M | $18.1M | 0.01% | -999K |
| Two Sigma Investments | 2026-06-30 | 697K | $10.2M | 0.01% | -284K |
| AQR Capital Management | 2026-06-30 | 542K | $7.9M | 0.00% | +98K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$322.9M of operating cash flow.
- Cash
- $419.4M
- Equity
- $630.0M
- Total assets
- $752.2M
- Shares outstanding
- 797,749,602
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | -$215.7M | n/a | -0.28 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$189.4M | n/a | -0.24 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$219.2M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$231.8M | n/a | -0.31 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$565.7M | n/a | -0.76 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$62.9M | n/a | -0.09 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$61.2M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $0 | -$56.3M | n/a | -0.08 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$1.08B | -$322.9M | $657K | n/a | n/a |
| FY 2024 | 2024-12-31 | $0 | -$221.3M | -$142.1M | $139K | n/a | n/a |
| FY 2023 | 2023-12-31 | $0 | -$614.9M | -$76.8M | $128K | n/a | n/a |
| FY 2022 | 2022-12-31 | $705K | -$78.8M | -$41.6M | $624K | n/a | n/a |
| FY 2021 | 2021-12-31 | $1.8M | -$88.6M | -$72.6M | $306K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-17 from the cover page.
What this page is
Summit Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Summit Therapeutics (SMMT), SEC CIK 1599298, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-09-30.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-10-09.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-14.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-23.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-06-12.JSON and CSV
- Company record
- EDGAR filing index for CIK 1599298Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ALKSAlkermes
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
Datasets
Frequently Asked Questions
How much of SMMT is sold short?
What is SMMT's daily short volume?
Does SMMT have fails to deliver?
Are SMMT insiders buying or selling?
What did SMMT report last quarter?
Which tracked 13F managers own SMMT?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.